The bacterial infections drug developer, based on research at Harvard Medical School, has gone public.

Spero Therapeutics, a US-based biopharmaceutical company based on research at Harvard University and backed by spinout-focused investment firm Osage University Partners, has raised $77m in its initial public offering.

The company issued 5 million shares on the Nasdaq Global Select Market priced at $14.00 each, at the foot of the IPO’s $14 to $16 range. The underwriters have a 30-day option to buy another 825,000 shares, which would lift the size of the offering to $88.6m.

Spero is working…